NFKB1 and neoplasm: Both drugs greatly extended the lifespan of C26-bearing mice, and though lurbinectedin and trabectedin did not protect C26-bearing mice from muscle wasting, lurbinectedin strikingly reduced NF-kB/PAX7-related muscle inflammation and splenomegaly, without affecting tumor growth [157].